Skip to main navigation
Skip to search
Skip to main content
Region Zealand Home
Help & FAQ
Link opens in a new tab
Dansk
English
Search content at Region Zealand
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Courses
Press/Media
Impacts
Cytomegalovirus Infection in a Multiple Sclerosis Patient on Dimethyl Fumarate
Nicolai Larsen
*
*
Corresponding author for this work
Medicine (NSR)
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
Overview
Fingerprint
Fingerprint
Explore the research areas of 'Cytomegalovirus Infection in a Multiple Sclerosis Patient on Dimethyl Fumarate'.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Sclerosis Treatment
100%
Dimethyl Fumarate
100%
Cytomegalovirus Infection
100%
Multiple Sclerosis
37%
Lymphocyte Count
12%
Elevated Liver Enzymes
12%
Relapsing-remitting multiple Sclerosis
12%
Young Males
12%
Potential Relationships
12%
Rituximab
12%
Hepatitis A
12%
Primary Infection
12%
Epstein-Barr Virus
12%
Splenomegaly
12%
Liver Enzymes
12%
Herpes Simplex Virus
12%
Antiretroviral Therapy
12%
Alemtuzumab
12%
Relapsing-remitting MS
12%
Ocrelizumab
12%
Lymphopenia
12%
MRI Lesions
12%
Viral DNA
12%
Immune Modulation
12%
Cytomegalovirus Antigenemia
12%
DNA Level
12%
Varicella
12%
Normal Lymphocytes
12%
Viral Panel
12%
Cytomegalovirus Reactivation
12%
Infection Reactivation
12%
Cytomegalovirus DNA
12%
Medicine and Dentistry
Multiple Sclerosis
100%
Fumaric Acid Dimethyl Ester
100%
Cytomegalovirus Infection
100%
Cytomegalovirus
37%
Immunoglobulin M
25%
Magnetic Resonance Imaging
12%
Virus DNA
12%
Elevated Transaminases
12%
Rituximab
12%
Hepatitis A
12%
Splenomegaly
12%
Epstein Barr Virus
12%
Primary Infection
12%
Immunomodulation
12%
Liver Enzyme
12%
Antiviral Therapy
12%
Herpes Simplex Virus
12%
Chickenpox
12%
Lymphocytopenia
12%
Lymphocyte
12%
Alemtuzumab
12%
Immunology and Microbiology
Multiple Sclerosis
100%
Fumaric Acid Dimethyl Ester
100%
Cytomegalovirus Infection
100%
Cytomegalovirus
37%
Immunoglobulin M
25%
Lymphocyte Count
12%
Magnetic Resonance Imaging
12%
Relapsing Remitting Multiple Sclerosis
12%
Immunomodulation
12%
Rituximab
12%
Serology
12%
Hepatitis A
12%
Infectious Disease
12%
Herpes Simplex Virus
12%
Lymphocytopenia
12%
DNA Virus
12%
Epstein Barr Virus
12%
Infection
12%
Chickenpox
12%
Ocrelizumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Fumaric Acid Dimethyl Ester
100%
Multiple Sclerosis
100%
Cytomegalovirus Infection
100%
Cytomegalovirus
37%
Immunoglobulin M
25%
Virus DNA
12%
Rituximab
12%
Hepatitis A
12%
Primary Infection
12%
Epstein-Barr Virus
12%
Splenomegaly
12%
Alemtuzumab
12%
Lymphocytopenia
12%
Liver Enzyme
12%
Antiviral Therapy
12%